Johnson & Johnson (NYSE:JNJ) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Johnson & Johnson (NYSE:JNJFree Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $215.00 price objective on the stock.

JNJ has been the subject of several other reports. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a neutral rating for the company in a research note on Wednesday, April 17th. HSBC upgraded Johnson & Johnson from a hold rating to a buy rating and raised their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Royal Bank of Canada restated an outperform rating and issued a $175.00 target price on shares of Johnson & Johnson in a research note on Monday, June 17th. The Goldman Sachs Group began coverage on Johnson & Johnson in a research note on Thursday, May 30th. They issued a neutral rating and a $160.00 target price for the company. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $168.00 to $167.00 and set an equal weight rating for the company in a research note on Wednesday, April 17th. Eight equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus price target of $174.07.

Check Out Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $148.75 on Thursday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The stock has a fifty day moving average price of $148.05 and a two-hundred day moving average price of $154.33. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The firm has a market capitalization of $357.99 billion, a P/E ratio of 9.27, a P/E/G ratio of 2.46 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period in the prior year, the company posted $2.68 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. As a group, analysts anticipate that Johnson & Johnson will post 10.63 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st were issued a dividend of $1.24 per share. The ex-dividend date was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.33%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors have recently modified their holdings of JNJ. Norges Bank bought a new position in shares of Johnson & Johnson during the 4th quarter valued at about $4,071,642,000. Wellington Management Group LLP raised its position in Johnson & Johnson by 16.4% in the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock valued at $3,764,852,000 after buying an additional 3,391,657 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Johnson & Johnson by 16.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock valued at $3,453,978,000 after buying an additional 3,139,499 shares during the last quarter. Swedbank AB acquired a new stake in Johnson & Johnson in the 1st quarter valued at approximately $331,178,000. Finally, International Assets Investment Management LLC raised its position in Johnson & Johnson by 7,875.8% in the 4th quarter. International Assets Investment Management LLC now owns 2,090,384 shares of the company’s stock valued at $327,647,000 after buying an additional 2,064,175 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

See Also

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.